Post Approval Study - Evaluate the Long-Term Safety and Effectiveness of the WEB Device
Purpose
A prospective, multicenter, single arm, interventional study. The target patient population for this study are adult subjects with WNBAs of the anterior and posterior intracranial circulation. The primary effectiveness outcome of the study is adequate intracranial aneurysm occlusion on the 1 year angiogram as adjudicated by a core laboratory.
Condition
- Wide Neck Bifurcation Intracranial Aneurysms
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Patient must be ≥ 18 at the time of screening - Patient must have a single ruptured or unruptured IA requiring treatment - Patient must sign and date an IRN approved written informed consent prior to initiation of any study procedures
Exclusion Criteria
- Patient has an IA with characteristics unsuitable for endovascular treatment - Patient has conditions placing them at high risk for ischemic stroke or has exhibited ischemic symptoms such as transient ischemic attacks, minor strokes, or stroke-in-evolution within the prior 30 days - Patient has had an SAH from a non-index IA or other intracranial hemorrhage within 90 days - Patient index IA was previously treated - Patient is pregnant
Study Design
- Phase
- N/A
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Single Group Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Other WEB Aneurysm Embolization Device |
WEB Aneurysm Embolization Device The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms. The intended therapeutic effect of the WEB device is to line the neck of the aneurysm with a metallic structure that disrupts the inflow of blood, causing hemostasis within the aneurysm sac, and leading to thrombus formation within the implant. |
|
Recruiting Locations
Hollywood 4158928, Florida 4155751 33021
Orlando 4167147, Florida 4155751 32806
Honolulu 5856195, Hawaii 5855797 96813
Iowa City 4862034, Iowa 4862182 52242
Kansas City 4273837, Kansas 4273857 66160
Lexington 4297983, Kentucky 6254925 40503
Lexington 4297983, Kentucky 6254925 40536
Shreveport 4341513, Louisiana 4331987 71103
Baltimore 4347778, Maryland 4361885 21201
Baltimore 4347778, Maryland 4361885 21287
Worcester 4956184, Massachusetts 6254926 01655
Minneapolis 5037649, Minnesota 5037779 55407
St Louis 4407066, Missouri 4398678 63110
Albany 5106834, New York 5128638 12208
Buffalo 5110629, New York 5128638 14203
Manhasset 5125766, New York 5128638 11030
Stony Brook 5139865, New York 5128638 11794
The Bronx 5110266, New York 5128638 10467
Durham 4464368, North Carolina 4482348 27710
Columbus 4509177, Ohio 5165418 43210
Columbus 4509177, Ohio 5165418 43214
Toledo 5174035, Ohio 5165418 43606
Oklahoma City 4544349, Oklahoma 4544379 73104
Philadelphia 4560349, Pennsylvania 6254927 19104
Philadelphia 4560349, Pennsylvania 6254927 19107
Memphis 4641239, Tennessee 4662168 38120
Morgantown 4815352, West Virginia 4826850 26506
More Details
- NCT ID
- NCT04839705
- Status
- Recruiting
- Sponsor
- Microvention-Terumo, Inc.